5-氨基-6-甲氧基-1,3-二氢-2H-苯并咪唑-2-酮 | 65740-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-氨基-6-甲氧基-1,3-二氢-2H-苯并咪唑-2-酮
• 英文名称: 5-amino-6-methoxy-1,3-dihydro-2H-benzimidazol-2-one
• 英文别名: 5-amino-6-methoxy-1,3-dihydrobenzimidazol-2-one
• CAS: 65740-56-9
• 化学式: C₈H₉N₃O₂
• mdl: MFCD10686599
• 分子量: 179.178
• InChiKey: KIZFSHBBEAAUOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  76.4
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险标志：
  GHS07
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  5-氨基-6-甲氧基-1,3-二氢-2H-苯并咪唑-2-酮 、 2,3-二氯苯磺酰氯 在 吡啶 作用下， 以54%的产率得到2,3-dichloro-N-(6-methoxy-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide
  参考文献：
  名称：

  Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists

  摘要：

  A knowledge-based library of 2,3-dichlorophenylsulfonyl derivatives of commercially available aryl amines was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. Hits were required to be more potent than an existing indazole series, have better physicochemical properties (clogP <3.5, chrom logD₇.₄ <5.3 and CLND solubility >116 μg/mL), and be stable to acid and light. The benzimidazol-2-one core was identified as a hit suitable for further investigation. Substitution at N1 with small alkyl groups was tolerated; however, these analogues were inactive in the whole blood assay (pA₂ <5). Azabenzimidazolone analogues were all found to be active, with compound 38 exhibiting whole blood activity of 6.1, low molecular weight (389) and chrom logD₇.₄ (2.4), high LE (0.43), and solubility (152 μg/mL). In addition, 38 had human serum albumin binding of around 93% and met all the criteria for progression to lead optimisation.

  DOI：

  10.1016/j.bmc.2014.05.021

文献信息

• [EN] OXAZOLOBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXAZOLOBENZIMIDAZOLE
  申请人：MERCK & CO INC

  公开号：WO2009140163A1

  公开（公告）日：2009-11-19

  The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及噁唑基苯并咪唑衍生物，它们是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病，以及代谢型谷氨酸受体参与的疾病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗代谢型谷氨酸受体参与的这类疾病中使用这些化合物和组合物。
• SUBSTITUTED PYRROLOPYRIMIDINES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150133426A1

  公开（公告）日：2015-05-14

  The present invention relates to substituted pyrrolopyrimidine compounds general formula I: in which A, X, R 1 , R 2 , m and n are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及替代吡咯吡嘧啶化合物通式I：其中A、X、R1、R2、m和n如本文所述和定义的那样，以及制备所述化合物的方法，用于制备所述化合物的中间体化合物，包含所述化合物的制药组合物和组合物，以及用于制造治疗或预防疾病的制药组合物的使用，特别是治疗或预防增殖过度和/或血管生成障碍的疾病，作为唯一的治疗剂或与其他活性成分组合使用。
• OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING AN AMINOBENZIMIDAZOLONE OXIDATION BASE AND A METAL CATALYST
  申请人：L'OREAL

  公开号：US20160136077A1

  公开（公告）日：2016-05-19

  The invention relates to a process for dyeing keratin fibres, comprising the use of one or more metal catalysts and of a composition (A) comprising: —one or more oxidizing agents, and —at least one aminobenzimidazole oxidation base of formula (I) in which the radicals R1 to R5 represent, independently of each other, a hydrogen atom; a halogen atom; a C1-C6 alkyl radical; a C1-C6 alkoxy radical; a C1-C6 dialkylamino radical; a carboxylic radical (—COOH); a sulfonic radical (—S03H); a phenyl radical; a sat orated or unsaturated 5- to 7-membered heterocyclic radical, comprising one or more heteroatoms chosen from N, O and S.
• WATER-BASED RESIN WITH ELASTICITY FOR APPLICATIONS IN CEMENTING AND SUBTERRANEAN STRUCTURES
  申请人：Saudi Arabian Oil Company

  公开号：US20220017811A1

  公开（公告）日：2022-01-20

  This disclosure relates to compositions including a poly-alkene maleic anhydride copolymer, a PEG, and a crosslinker selected from an ethyleneamine, a benzenetricarboxylic acid, a benzimidazole, and combinations thereof. The poly-alkene maleic anhydride copolymer includes repeat units I and II: where R 1 , R 1′ , R 2 , and R 2′ are each independently selected from —H and —(C 1 -C 5 )alkyl. The disclosure also provides methods of treating a subterranean formation or cement construction using the compositions.
• US4220586A
  申请人：——

  公开号：US4220586A

  公开（公告）日：1980-09-02